Oscar Health Inc expected to post a loss of 17 cents a share - Earnings Preview

Oscar Health

06/11/2024 14:34

* Oscar Health Inc  OSCR.N   OSCR.K  is expected to show a
rise in
quarterly revenue when it reports  results on November 7 for the
period ending September 30 2024
    * The New York City-based  company is expected to report a
62.4% increase in revenue to $2.339 billion from $1.44 billion a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Oscar Health Inc is for
a loss
of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Oscar
Health Inc
is 27.50​, above​ its last closing price of $18.34. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   0.17        0.16       0.20      Beat    23.7
 Mar. 31 0001  0.27        0.27       0.62      Beat    127.9
 Dec. 31 2023  -0.73       -0.72      -0.66     Beat    8.7​
 Sep. 30 2023  -0.47       -0.47      -0.29     Beat    38.6
 ​​Jun.        -0.22       -0.23      -0.07     Beat    69.6
 30 2023                                                
 Mar. 31 2023  -0.04       -0.05      -0.18     Missed  -254.7
                                                        ​
 Dec. 31 2022  -1.09       -1.16      -1.05     Beat    9.5
 Sep. 30 2022  -0.72       -0.73      -0.91     Missed  -24.6
 This summary was machine generated November 6 at 14:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)